Peer Review
editHello MBae2. This is Priscilla Molina and these are some of my thoughts on your article additions/overall article.
Introduction:
I felt like this was pretty concise. I got quickly informed about your topic. I don't see that the last sentence is of pivotal importance for the introduction and can be mentioned instead possibly under your "Mechanism" section.
Structure:
I'm not too sure if this would be too much detail but under the precursor section I would explain some of these locations or at least provide links for the reader to click on where they can learn more about each component that you mention, such as reverse transcriptase and p6pol.
Your "Mature protease" section in contrast is a lot more easy to follow and has a good source of references if one is confused about a word you mentioned in your explanation.
Function:
In order to facilitate the readers understanding of what you are trying to do by explaining the process of viral HIV-RNA entering the cell, I would state why you are doing that. I would even move your sentence "HIV-1 PR serves a dual purpose" to the beginning and then state under what conditions the HIV1 PR serves its purpose.
Synthesis:
Your explanation is good here but again if you would reference or explain more about the different location you mention, it would be easier to follow (maybe even having a diagram of where in the cell this is taking place or simply showing where the N-terminus and p6pol
are located.
Mechanism:
I followed your explanation of the mechanism well and I do feel like it was concise enough. Again, I would try and reference, for example, base catalysis and similar ideas like that so if someone were not as familiar with this concept they can better understand what the HIV1 PR is doing.
As a drug target:
I followed this well as well and appreciated your concise references .
Overall, I think this was a very interesting article to read. It was not biased at any point. Although the images you provided were helpful, I would encourage you to provide an images that show the HIV 1 PR in action in the cell or at least its location when it is active.
Peer Review
editHello! I'm jealous that your article has relevance to 153A (it discusses catalysis a lot which must have helped you study!!)
Anyways, after reading the article I compared the previous version to the version where you added your information, so I could see where you edited things personally.
For the introduction, I feel like it could be improved by initially simplifying it to say something like "HIV1 protease is a type of enzyme that cleaves peptides known as a retroviral aspartyl protease" because opening with just "retroviral asparyl protease" is a little technical if people reading don't have background on enzymes and such.
Overall there is good info, but to make it flow better I do have a few formatting suggestions:
I think merging the paragraph "Precursor" and the first paragraph of "Function" and moving it under the heading "Synthesis" would make more sense because the content seems more related to how the protease becomes mature. Also, "catalytic triad" is defined under "Mature Protease" but it is first mentioned under "Precursor," so defining catalytic triad at the first instance it is mentioned would be helpful.
Under "Mechanism," could you give context behind who Mariusz Jaskolski and colleagues are? Like their field of study, where they are from, things like that? Same with Ashraf Brik and Chi-Huey Wong. Also, you could make the heading a little more specific by changing it to "Mechanism of action" because just mechanism is a little broad.
I think the edits you made under "As a drug target" are very nicely written, so I don't have much to say there!
Lastly then, although what you wrote under "Mechanism" is very detailed and content-rich, it can be a little hard to follow. Would it be possible to provide diagrams instead?
Best of luck, Ellee
 | This user is a student editor in UCLA/Chem_153A_Honors_(Spring_2018). |
| | This user is a student editor in UCLA/Chem_153A_Honors_(Spring_2018). |
| | This user is a student editor in UCLA/Chem_153A_Honors_(Spring_2018). |
Hepatitis C virus internal ribosome entry site
| | This user is a student editor in UCLA/Chem_153A_Honors_(Spring_2018). |
| | This user is a student editor in UCLA/Chem_153A_Honors_(Spring_2018). |
| | This user is a student editor in UCLA/Chem_153A_Honors_(Spring_2018). |
| | This user is a student editor in UCLA/Chem_153A_Honors_(Spring_2018). |
| | This user is a student editor in UCLA/Chem_153A_Honors_(Spring_2018). |
| | This user is a student editor in UCLA/Chem_153A_Honors_(Spring_2018). |
My five preferences are as follow:
Talk:Hepatitis B immune globulin
| | This user is a student editor in UCLA/Chem_153A_Honors_(Spring_2018). |
| | This user is a student editor in UCLA/Chem_153A_Honors_(Spring_2018). |
| | This user is a student editor in UCLA/Chem_153A_Honors_(Spring_2018). |
| | This user is a student editor in UCLA/Chem_153A_Honors_(Spring_2018). |
Talk:(-)-alpha-terpineol synthase
| | This user is a student editor in UCLA/Chem_153A_Honors_(Spring_2018). |
These look fine. I'm not sure that Tac promoter has enough to add, and for viral pathogenesis it maybe a lot of figures that need to be made. - Dr. Tienson-Tseng
Bibliography
I have decided HIV-1 Protease as my article to edit. Attached are my sources.[1][2][3][4][5][6]
- ^ "HIV-1 Protease". Protein Data Bank. Retrieved 1 May 2018.
- ^ Brik, Ashraf; Wong, Chi-Huey (2002-11-26). "HIV-1 protease: mechanism and drug discovery". Organic & Biomolecular Chemistry. 1 (1): 5–14. doi:10.1039/b208248a. ISSN 1477-0520.
- ^ Huang, Xi; Britto, Manuel D.; Kear-Scott, Jamie L.; Boone, Christopher D.; Rocca, James R.; Simmerling, Carlos; Mckenna, Robert; Bieri, Michael; Gooley, Paul R. (2014-06-13). "The Role of Select Subtype Polymorphisms on HIV-1 Protease Conformational Sampling and Dynamics". Journal of Biological Chemistry. 289 (24): 17203–17214. doi:10.1074/jbc.M114.571836. ISSN 0021-9258. PMC 4059161. PMID 24742668.
{{cite journal}}: CS1 maint: PMC format (link) CS1 maint: unflagged free DOI (link) - ^ Wang, Yong; Lv, Zhengtong; Chu, Yuan (2015-04). "HIV protease inhibitors: a review of molecular selectivity and toxicity". HIV/AIDS - Research and Palliative Care. 7: 95. doi:10.2147/hiv.s79956. ISSN 1179-1373. PMC 4396582. PMID 25897264.
{{cite journal}}: Check date values in:|date=(help)CS1 maint: PMC format (link) CS1 maint: unflagged free DOI (link) - ^ Loeb, Daniel D.; Swanstrom, Ronald; Everitt, Lorraine; Manchester, Marianne; Stamper, Susan E.; Hutchison, Clyde A. (August 1989). "Complete mutagenesis of the HIV-1 protease". Nature. 340 (6232): 397–400. doi:10.1038/340397a0. ISSN 0028-0836.
- ^ Yilmaz, Nese Kurt; Schiffer, Celia A. (2017). Antimicrobial Drug Resistance. Springer, Cham. pp. 535–544. doi:10.1007/978-3-319-46718-4_35. ISBN 9783319467160.
1. HIV-1 Protease: This website elucidates the structure of this protein, such as the length of its sequence (99), number of subunits (2 unique, 3 total), and classification as a hydrolase/hydrolase inhibitor.
2.HIV-1 Protease - mechanism and drug discovery: The mechanism of the HIV-1 Protease was elucidated, especially its general category as an aspartic protease and similar catalytic mechanism, with the exception of the one-step process of the hydrolysis reaction.
3. Subtype Polymorphisms on HIV-1 Protease: Mutations on the HIV-1 Protease active site and on the surface of the protein can potentially lead to increased resistance of inhibiting drugs. Using a pulsed double-electron-electron-resonance (DEER) system, this paper works to elucidate these molecular mechanisms by which these polymorphisms can potentially increase drug resistance.
4. HIV Protease Inhibitors: This article provides a review of HIV-1 protease, namely (1) its main function (cleaving Gag and Gal-Pol polypeptide precursors at nine sites for processing mature, virally active proteins), (2) its inhibition mechanism via inhibitors binding to its active site, as well as (3) specific examples of inhibitors, (4) possible ancillary effects of inhibiting drugs on essential proteins, and (5) improvements of inhibiting drugs based on their water solubility and bioavailability.
5. Complete mutagenesis: This article described a mutagenesis and phenotypic-screening approach to determine the most functionally critical regions of HIV-1 protease.
6. Antimicrobial Drug Resistance -- I am also planning to reference this source...